<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57600">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02356198</url>
  </required_header>
  <id_info>
    <org_study_id>14-003143</org_study_id>
    <nct_id>NCT02356198</nct_id>
  </id_info>
  <brief_title>Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery</brief_title>
  <official_title>Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is prospective, randomized trial in which EXPAREL TAP block is compared to
      standard IT opioid administration, in relieving postoperative pain, decreasing length of
      stay, and use of narcotic medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective To assess efficacy of EXPAREL TAP blocks in improving pain scores for 48
      hours postoperatively, and in reducing total oral morphine equivalents (OME) use, compared
      to standard Intrathecal opioid administration (IT).

      Secondary Objective Assess the length of stay (LOS), postoperative ileus (POI) incidence,
      and the use of intravenous patient controlled analgesia (PCA) in patients that had EXPAREL
      TAP blocs compared to IT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores</measure>
    <time_frame>First 48 hours post op.</time_frame>
    <description>mean pain scores for 48 hours after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Post operative</time_frame>
    <description>Length of stay days post operative.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Conditions Requiring Colorectal Surgery</condition>
  <arm_group>
    <arm_group_label>TAP block (EXPAREL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20mL of injectable saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single injection intrathecal hydromorphone analgesia given preoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXPAREL</intervention_name>
    <description>transversus abdominis plane injection</description>
    <arm_group_label>TAP block (EXPAREL)</arm_group_label>
    <other_name>liposomal bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal hydromorphone</intervention_name>
    <description>Intrathecal opioid administration</description>
    <arm_group_label>IT</arm_group_label>
    <other_name>dilaudid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • All patients undergoing elective laparoscopic or open colorectal resections who are
             eligible for IT, and able to be enrolled in ERP.

               -  Age &gt;18 years

               -  BMI &lt;40

               -  Ability to understand and read English

        Exclusion Criteria:

          -  • Not able or unwilling to sign consent.

               -  Currently pregnant or lactating.

               -  Patients with chronic pain, requiring daily opiate use at time of surgery.

               -  Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.

               -  Patients requiring emergent surgery.

               -  Abdominoperineal resections

               -  Any contraindications to neuraxial analgesia (coagulopathy, localized infection
                  at the potential site of injection, pre-existing spinal canal pathology)

               -  Patients with a diagnosis of inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mauricia A Buchanan, RN</last_name>
    <phone>904-953-2596</phone>
    <email>buchanan.mauricia@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricia Buchanan, RN</last_name>
      <phone>904-953-2596</phone>
      <email>buchanan.mauricia@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 21, 2016</lastchanged_date>
  <firstreceived_date>January 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Dorin T. Colibaseanu, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
